Lee_2018_Exp.Mol.Med_50_61

Reference

Title : NDRG3 lowers the metastatic potential in prostate cancer as a feedback controller of hypoxia-inducible factors - Lee_2018_Exp.Mol.Med_50_61
Author(s) : Lee GY , Shin SH , Shin HW , Chun YS , Park JW
Ref : Exp Mol Med , 50 :61 , 2018
Abstract :

Expression of hypoxia-inducible factors (HIFs) and N-myc downstream-regulated gene 3 (NDRG3) are oxygen-dependently regulated by prolyl hydroxylase domain (PHD) enzymes. Little is known about the role of NDRG3 in the cellular adaptation to hypoxia, whereas the roles of HIFs are well understood. In this study, we investigated how NDRG3 affects the hypoxic response in prostate cancer cells. Compared with HIF-1alpha, hypoxic induction of NDRG3 was observed at a later phase. NDRG3 reduced hypoxic expression of HIF-1alpha by inhibiting AKT-driven translation of HIF1A mRNA. In addition, NDRG3 functionally inhibited HIF-1 by dissociating the coactivator p300 from HIF-1alpha. Accordingly, NDRG3 may fine-tune the HIF-1 signaling pathway to cope with long-term hypoxia. Of the diverse effects of HIF-1alpha on cancer progression, hypoxia-induced cell migration was investigated. In transwell chambers, NDRG3 negatively regulated the migration and invasion of prostate cancer cells under hypoxia. An informatics analysis using Gene Expression Omnibus (GEO) revealed that NDRG3 downregulation is associated with prostate cancer metastasis and high expression of HIF-1 downstream genes. In cancer tissue arrays, NDRG3 expression was lower in prostate cancer tissues with a Gleason score of 8 or greater and was inversely correlated with HIF-1alpha expression. Therefore, NDRG3 may have an anti-metastatic function in prostate cancer under a hypoxic microenvironment.

PubMedSearch : Lee_2018_Exp.Mol.Med_50_61
PubMedID: 29760417

Related information

Citations formats

Lee GY, Shin SH, Shin HW, Chun YS, Park JW (2018)
NDRG3 lowers the metastatic potential in prostate cancer as a feedback controller of hypoxia-inducible factors
Exp Mol Med 50 :61

Lee GY, Shin SH, Shin HW, Chun YS, Park JW (2018)
Exp Mol Med 50 :61